- Advertisement -

The number of weekly pediatric COVID-19 cases fell to a pandemic record low on September 9 with more than 243,000 infections, according to the latest report from the American Academy of Pediatrics.

Pediatric COVID-19 cases have recently seen exponential growth, the group notes, adding nearly 500,000 cases from August 26 to September 9, the most recent available statistics. The latest report shows a nearly 240% increase in weekly cases since the end of July, when 71,726 cases were reported.


Click here to find a COVID-19 vaccine near you

- Advertisement -

Earlier reports from the Pediatrics group, which included data for September 2, looked at weekly pediatric numbers COVID-19 At 251,781 infections climb the highest figure seen since the pandemic began. The group continues to urge further research on the long-term effects of the pandemic on children, including physical, emotional and mental health effects.

New York City schools reopen with vaccine mandate, no remote option

Overall, there have been more than 5.2 million COVID-19 cases in children since the pandemic began, although infections due to serious illnesses are uncommon, the latest report read.

The findings coincide with a continued increase in the rate of new hospital admissions for patients aged 0-17, reaching 0.50 admissions per 100,000 population as of 5 September. statistics From the Centers for Disease Control and Prevention (CDC). In early July, the rate was around 0.07 per 100,000. Adults over the age of 70 have the highest rate of new admissions, at about 8 per 100,000. As of the end of August, cases per 100,000 weekly were highest among adolescents aged 16-17, at 326.9, compared to all other age groups.

Vaping linked to increased risk of eating disorders among US college students

Children under the age of 12 remain ineligible for the COVID-19 vaccine, although shots may become available later in the fall. Former FDA commissioner and Pfizer board member Dr. Scott Gottlieb told CNBC that Pfizer will likely request emergency approval for the use of its vaccine among children between the ages of 5 and 11 in October, with possible authorization in late fall or early winter. Meanwhile, Moderna’s trial data for children ages 5-11 could arrive in late fall or early winter, insider informed of.

“The FDA is working round-the-clock to support the process of making COVID-19 vaccines available to children,” the Food and Drug Administration wrote on September 10. Statement, adding in part, “This process is complex and relies on robust manufacturer tests and data.”